Table 4.

Responses to pembrolizumab and Y90 combination treatment by mRECIST 1.1.

mRECIST	Current mRECIST response		Best mRECIST response
	N	Percent (95% CI)	Counts	Percent (95% CI)
ORR	9	37.5 (18.8%, 59.4%)	9	36.0 (18.0%, 57.5%)
CR	4	16.7 (4.7%, 37.4%)	4	16.0 (4.5%, 36.1%)
PR	5	20.8 (7.1%, 42.2%)	5	20.0 (6.8%, 40.7%)
SD	6	25.0 (9.8%, 46.7%)	14	56.0 (34.9%, 75.6%)
PD	9	37.5 (18.8%, 59.4%)	2	8.0 (1.0%, 26.0%)

mRECIST based on 24 patients: patients 1024 and 1026 are excluded, patients 1006 and 1031 have missing mRECIST, and patient 0007 has NE for mRECIST. Best mRECIST based on 25 patients: patient 0007 has PR for best mRECIST.